COMPASS Pathways stock (GB00BKLLQZ68): short interest drops as Nasdaq-listed shares trade in double digits

COMPASS Pathways, listed on Nasdaq under the ticker CMPS, remains in the spotlight for US investors after its stock closed at USD 13.06 on 05/29/2026, up 9.56% for the day, while after-hours trading quoted USD 12.90, according to MarketBeat as of 05/29/2026.

The UK-based mental health company, whose primary listing is on the Nasdaq in the United States, is drawing attention as short interest declined to about 7.70 million shares, or 5.87% of float, as of 05/15/2026, a drop of 21.18% from the previous report, based on data from MarketBeat as of 05/15/2026.

The stock traded at USD 13.06 on 05/29/2026 on Nasdaq, according to MarketBeat as of 05/29/2026.

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

COMPASS Pathways: core business model

COMPASS Pathways focuses on advancing psychedelic-derived mental health treatments through late-stage clinical development, targeting conditions such as treatment-resistant depression where existing therapies often fall short.

What banks and research houses say about COMPASS Pathways

Analyst coverage for COMPASS Pathways reflects the high-risk, high-reward nature of late-stage biotechnology companies working on novel psychiatric therapies, with various US and UK research houses tracking the progress of its clinical programs and regulatory milestones.

According to data compiled by MarketBeat as of 05/29/2026, the stock has been followed by several Wall Street firms that factor in trial readouts, funding visibility and potential market size for psychedelics-based treatments when setting their views, although individual price targets and ratings can diverge given the binary nature of clinical and regulatory outcomes.

Conclusion

With COMPASS Pathways shares trading above USD 13 on Nasdaq and short interest down more than one-fifth in mid-May 2026, market positioning around the stock has shifted notably in recent weeks. The continued monitoring of analyst commentary and clinical milestones will remain crucial for investors assessing the evolving risk-reward profile of this UK-based psychedelics developer.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.